Company profile: Oncternal Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage oncology treatments, developing a pipeline including ONCT-808, a ROR1-targeting autologous CAR T in Phase 1/2 for relapsed or refractory aggressive B-cell lymphoma; ONCT-534, a dual-action androgen receptor inhibitor for metastatic castration-resistant prostate cancer; and zilovertamab, a ROR1-targeting monoclonal antibody evaluated with other treatments for various cancers.
Products and services
- ONCT-534: A dual-action androgen receptor inhibitor (DAARI-class) developed for metastatic castration-resistant prostate cancer, advancing through development
- ONCT-808: An autologous CAR T therapy targeting ROR1, in Phase 1/2 clinical testing for relapsed or refractory aggressive B‑cell lymphoma
- Zilovertamab: A monoclonal, ROR1-targeting antibody evaluated in combination with other treatments across various cancers, integrated within multi-therapy regimens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oncternal Therapeutics
Eclipse Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics discovery and development targeting cancer stem cells (CSCs) and other innovative cancer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eclipse Therapeutics company profile →
Immunitas Therapeutics
HQ: United States
Website
- Description: Provider of single-cell genomics and machine learning-based drug discovery to modulate oncology targets; antibody discovery and engineering; biomarker development; and IMT-009, an immuno-oncology a-CD161 mAb in clinical evaluation for solid tumors and hematological malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunitas Therapeutics company profile →
Predilife
HQ: France
Website
- Description: Provider of predictive medicine solutions that combine proven medical techniques (genetic testing, medical imaging) with mathematical models and extensive statistical data to assess individual risk profiles for serious diseases. Offers a breast cancer five-year risk assessment with personalized follow-up and recommendations, and multi-pathology assessments for major cancers and cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Predilife company profile →
ThromboDx
HQ: The Netherlands
Website
- Description: Provider of blood-based, platelet-powered molecular diagnostics, developed and commercialized through a proprietary technology platform that addresses the need for an easily accessible, minimally invasive source; with offices in Amsterdam, The Netherlands.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ThromboDx company profile →
Galecto
HQ: Denmark
Website
- Description: Provider of clinical-stage small molecule therapies for fibrosis and cancer. Develops inhibitors including GB0139, an inhaled galectin-3 inhibitor for severe fibrotic lung diseases such as idiopathic pulmonary fibrosis; GB1211, an oral galectin-3 inhibitor for decompensated cirrhosis; and GB2064, a LOXL2 inhibitor for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galecto company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oncternal Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oncternal Therapeutics
2.2 - Growth funds investing in similar companies to Oncternal Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oncternal Therapeutics
4.2 - Public trading comparable groups for Oncternal Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →